Last reviewed · How we verify
ICS/LABA and Montelukast
This combination reduces airway inflammation and bronchoconstriction by suppressing inflammatory mediators and relaxing airway smooth muscle.
This combination reduces airway inflammation and bronchoconstriction by suppressing inflammatory mediators and relaxing airway smooth muscle. Used for Asthma (maintenance and reliever therapy), Chronic obstructive pulmonary disease (COPD) with asthmatic features.
At a glance
| Generic name | ICS/LABA and Montelukast |
|---|---|
| Also known as | Inhaled corticosteroid/β2 agonist: Symbicort Turbuhaler, Montelukast: Singulair |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University |
| Drug class | ICS/LABA combination with leukotriene receptor antagonist |
| Target | Glucocorticoid receptor, beta-2 adrenergic receptor, cysteinyl leukotriene receptor (CysLT1) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
The inhaled corticosteroid (ICS) component suppresses inflammatory pathways and reduces eosinophil recruitment in the airways. The long-acting beta-2 agonist (LABA) relaxes bronchial smooth muscle and provides sustained bronchodilation. Montelukast, a cysteinyl leukotriene receptor antagonist, blocks leukotriene-mediated inflammation and bronchoconstriction, providing complementary anti-inflammatory and bronchodilatory effects.
Approved indications
- Asthma (maintenance and reliever therapy)
- Chronic obstructive pulmonary disease (COPD) with asthmatic features
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Muscle pain
Key clinical trials
- Asthma Research in Children and Adolescents
- Clinical Characteristics and Treatment of Chest Tightness Variant Asthma (NA)
- Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma (PHASE4)
- Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma (PHASE4)
- Effect of Montelukast on the Airway Remodeling (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: